In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e12551-e12551
Abstract:
e12551 Background: Breast cancer (BC) is still one of the main causes of death in women due to the tumor recurrence and/or resistance to anticancer therapy. The criteria to assess the risk of tumor progression in breast cancer after 2 chemotherapy cycles are required. The purpose of the study was to analyze blood levels of TGFβ, TGFR2, TNF, TNFα, TNFR1, TNFR2, MMP-9 and CD-44 in patients with various BC subtypes before and after 2 chemotherapy cycles. Methods: The study included 42 patients with various BC subtypes: luminal A, luminal B and triple-negative BC (TNBC). Levels of TGFβ, TGFR2, TNF, TNFR1, TNFR2, CD-44, MMP-9 were measured by ELISA in the blood of all patients prior to anticancer therapy and after 2 chemotherapy cycles. Statistical processing of results was performed using the Statistika 6.0 software by the Student’s t-test. Results: Levels of TGFβ, TGFR2, TNF, TNFα, TNFR1, TNFR2, CD-44, MMP-9 in patients with all BC subtypes were high before the treatment. After 2 chemotherapy cycles, the values decreased statistically significantly in all BC subtypes: CD-44 decreased by 25.2%, 30% and 54.7% in luminal A, luminal B and TNBC, respectively; TNFα – by 26.2%, 48.3% and 50.8%, respectively; TNFα-R1 – by 52.1%, 39.2% and 50.3% respectively; TNFα-R2 – by 31.7%, 32.8% and 41.9% respectively; MMP-9 – 35.3%, 32.6% and 43.3% respectively. The patients remained in remission for 3 years. When the levels were high or did not differ from initial values, the tumor progressed. Conclusions: We identified a set of criteria allowing with high probability to determine the growth and progression of tumors in various subtypes of breast cancer after two cycles of chemotherapy. A decrease in the levels of TGF-β, TNF, MMP-9, and CD-44 demonstrates remission; stabilization or increase of these indicators leads to further early progression of the disease.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2020.38.15_suppl.e12551
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2020
detail.hit.zdb_id:
2005181-5
